An RNA-modifying enzyme linked to cancer and neurological disorders selects its targets by recognizing specific RNA shapes and sequences, according to a study by UT Southwestern Medical Center researchers.
An experimental antibody treatment that binds to a protein known as PCDH7 shrank tumors in preclinical models of non-small cell lung cancer, even those resistant to a targeted therapy, a study led by UT Southwestern Medical Center researchers showed. This discovery could eventually lead to a new class of drugs to treat NSCLC and potentially other cancers.
